Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2014
|
| gptkbp:ATCCode |
A10BK01
|
| gptkbp:contraindication |
type 1 diabetes
severe renal impairment |
| gptkbp:drugClass |
SGLT2 inhibitor
|
| gptkbp:eliminatedIn |
urine
feces |
| gptkbp:form |
gptkb:tablet
10 mg 5 mg |
| gptkbp:genericName |
gptkb:dapagliflozin
|
| gptkbp:halfLife |
12.9 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Farxiga
|
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:manufacturer |
gptkb:AstraZeneca
|
| gptkbp:marketedAs |
gptkb:Forxiga
|
| gptkbp:mechanismOfAction |
inhibits SGLT2 in the kidney
|
| gptkbp:pregnancyCategory |
Not recommended
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:reduces |
blood glucose
progression of kidney disease risk of hospitalization for heart failure |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
urinary tract infection
dehydration hypotension genital infection |
| gptkbp:usedFor |
gptkb:type_2_diabetes
heart failure chronic kidney disease |
| gptkbp:bfsParent |
gptkb:AstraZeneca
|
| gptkbp:bfsLayer |
5
|